As of the latest Form 4 filed Jun 1, 2026.
What Crispr Therapeutics AG insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 30 most recent filings for CRSP.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-01 | 2026-05-29 | Patel Naimish Chief Medical Officer | SSale | −3.79K | $55.62 | $211K | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-28 | Patel Naimish, Chief Medical Officer | MExercise | +10.0K | — | — | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-23 | KASINGER JAMES R. General Counsel and Secretary | SSale | −3.18K | $46.78 | $149K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-23 | Kulkarni Samarth Chief Executive Officer | SSale | −10.0K | $46.78 | $469K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-23 | Prasad Raju Chief Financial Officer | SSale | −3.71K | $46.78 | $173K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | KASINGER JAMES R. General Counsel and Secretary | MExercise | +6.25K | — | — | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Kulkarni Samarth Chief Executive Officer | MExercise | +19.7K | — | — | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Prasad Raju Chief Financial Officer | MExercise | +6.25K | — | — | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Patel Naimish Chief Medical Officer | SSale | −3.15K | $48.26 | $152K | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Prasad Raju Chief Financial Officer | GGift | −750.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Prasad Raju, Chief Financial Officer | SSale | −4.02K | $48.26 | $194K | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Prasad Raju, Chief Financial Officer | SSale | −5.85K | $48.26 | $282K | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | KASINGER JAMES R. General Counsel and Secretary | SSale | −3.45K | $48.26 | $166K | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-16 | Kulkarni Samarth Chief Executive Officer | SSale | −10.3K | $48.26 | $499K | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-14 | Patel Naimish Chief Medical Officer | MExercise | +8.13K | — | — | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-14 | Prasad Raju Chief Financial Officer | MExercise | +6.88K | — | — | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-14 | Prasad Raju, Chief Financial Officer | MExercise | +10.0K | — | — | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-14 | KASINGER JAMES R. General Counsel and Secretary | MExercise | +6.88K | — | — | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-14 | Kulkarni Samarth Chief Executive Officer | MExercise | +20.6K | — | — | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-11 | KASINGER JAMES R. General Counsel and Secretary | SSale | −2.80K | $52.80 | $148K | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-11 | Kulkarni Samarth Chief Executive Officer | SSale | −9.80K | $52.80 | $517K | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | KASINGER JAMES R. General Counsel and Secretary | MExercise | +5.50K | — | — | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Kulkarni Samarth Chief Executive Officer | MExercise | +19.3K | — | — | No | Form 4 ↗ |
| 2026-02-20 | 2026-02-19 | Kulkarni Samarth Chief Executive Officer | SSale | −6.97K | $52.58 | $366K | No | Form 4 ↗ |
| 2026-02-20 | 2026-02-19 | KASINGER JAMES R. General Counsel and Secretary | SSale | −2.11K | $52.58 | $111K | No | Form 4 ↗ |
| 2026-02-20 | 2026-02-18 | Kulkarni Samarth Chief Executive Officer | MExercise | +13.3K | — | — | No | Form 4 ↗ |
| 2026-02-20 | 2026-02-18 | KASINGER JAMES R. General Counsel and Secretary | MExercise | +3.83K | — | — | No | Form 4 ↗ |
| 2026-01-27 | 2025-04-03 | Patel Naimish Chief Medical Officer | PPurchase | +1.51K | $32.96 | $49.7K | No | Form 4 ↗ |
| 2026-01-26 | 2026-01-22 | Prasad Raju Chief Financial Officer | SSale | −35.0K | $60.19 | $2.10M | Yes (planned) | Form 4 ↗ |
| 2026-01-26 | 2026-01-22 | Prasad Raju, Chief Financial Officer | MExercise | +35.0K | $45.15 | $1.58M | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also CRSP’s full analysis or the market-wide insider trading feed. The tabs above jump to CRSP’s other SEC data.
Source: SEC Form 4 filings for CRSP, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.